exposure to dox Search Results


aplio xv  (TOSHIBA Medical)
90
TOSHIBA Medical aplio xv
Aplio Xv, supplied by TOSHIBA Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/aplio+xv/pmc07662380-123-6-10
Average 90 stars, based on 1 article reviews
aplio xv - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
doxorubicin  (Alphamed INC)
90
Alphamed INC doxorubicin
Doxorubicin, supplied by Alphamed INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/anthracyclines/pm24715690-142-12-33
Average 90 stars, based on 1 article reviews
doxorubicin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
drug-loaded qd nanocarrier complexes  (NanoCarrier Co)
90
NanoCarrier Co drug-loaded qd nanocarrier complexes
Drug Loaded Qd Nanocarrier Complexes, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/drug+loaded+qd+nanocarrier+complexes/pmc05028086-131-6-8
Average 90 stars, based on 1 article reviews
drug-loaded qd nanocarrier complexes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
exposure to dox  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology exposure to dox
Exposure To Dox, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/Doxycycline+monohydrate/pmc05302920-131-9-12
Average 93 stars, based on 1 article reviews
exposure to dox - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
adriblastina  (Farmitalia Carlo Erba Srl)
90
Farmitalia Carlo Erba Srl adriblastina
Adriblastina, supplied by Farmitalia Carlo Erba Srl, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/adriblastina/pm09607319-29-9-12
Average 90 stars, based on 1 article reviews
adriblastina - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ap positive colonies  (LI-COR)
95
LI-COR ap positive colonies
Ap Positive Colonies, supplied by LI-COR, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/NEWBLOT+N+STRIPPING+BFFR/pm27558603-49-67-98
Average 95 stars, based on 1 article reviews
ap positive colonies - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
doxorubicin dox  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology doxorubicin dox
Doxorubicin Dox, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/Doxorubicin/pmc04459854-40-13-15
Average 93 stars, based on 1 article reviews
doxorubicin dox - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
doxorubicin dox  (Selleck Chemicals)
96
Selleck Chemicals doxorubicin dox
Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L <t>doxorubicin</t> for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.
Doxorubicin Dox, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/Doxycycline/pm30414989-266-5-7
Average 96 stars, based on 1 article reviews
doxorubicin dox - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
dox chemotherapy  (Nagai Nori USA INC)
90
Nagai Nori USA INC dox chemotherapy
Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L <t>doxorubicin</t> for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.
Dox Chemotherapy, supplied by Nagai Nori USA INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/dox+chemotherapy/pm31215040-179-21-13
Average 90 stars, based on 1 article reviews
dox chemotherapy - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
dox exposure  (Beyotime)
99
Beyotime dox exposure
Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L <t>doxorubicin</t> for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.
Dox Exposure, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/Mito-Tracker+Green/pm37703929-77-3-13
Average 99 stars, based on 1 article reviews
dox exposure - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
dox  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology dox
Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L <t>doxorubicin</t> for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.
Dox, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exposure+to+dox/Doxazosin/pm25079687-41-41-42
Average 93 stars, based on 1 article reviews
dox - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L doxorubicin for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.

Journal: Experimental hematology

Article Title: Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34 + CD38 - cells through iron chelation, induction of ROS, and inhibition of HIF1α expression.

doi: 10.1016/j.exphem.2018.10.010

Figure Lengend Snippet: Figure 4. Deferasirox exposure increases ROS levels. KG-1a cells were separated into CD34+CD38−and CD34+CD38+ fractions (A−G). CD34+CD38−CD123+ and CD34+CD38+CD123+ cells were isolated from newly diagnosed AML patients (n = 3) (A−D). All fractions were cul- tured with 5 mmol/L or 20 mmol/L deferasirox for the indicated times. (A) Representative flow cytometric analysis of ROS production using H2DCFDA staining in KG-1a and AML patient (specimen AML053) cell fractions exposed to deferasirox for 3 hours. (B) Relative ROS levels calculated as fold change of median fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML33, AML51, and AML53). (C) Representative flow cytometric overlays for mBCl fluorescence from KG-1a and AML patient (specimen AML057) cell fractions exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min or to 3 hours of 800 mmol/L NAC pretreatment + 30 min of 20 mmol/L deferasirox. (D) Relative free thiol groups levels as the fold change of median mBCl fluorescence intensity over unstained control § SEM (n = 3, patient samples: AML54, AML56, and AML57). (E) Representative flow cytometric overlays for MitoSOX fluorescence of CD34+CD38−and CD34+CD38+ KG-1a cells exposed to 5 mmol/L or 20 mmol/L deferasirox for 30 min. Exposure to 1−10 mmol/L doxorubicin for 18 hours was used as a positive control. (F) Relative superoxide levels as the fold change of median MitoSox fluorescence intensity over unstained control § SEM (n = 3). (G) CD34+CD38−and CD34+CD38+ KG-1a cells were exposed to 20 mmol/L deferasirox for 48 hours or pretreated with 400 mmol/L or 800 mmol/L NAC for 1 hour, then washed and treated with 20 mmol/L deferasirox for 48 hours or exposed to 50-100 mmol/L BSO for 48 hours. Apoptosis was evaluated by flow cytometry using Annexin V and 7-AAD. Percentages of apoptotic cells (Annexin V+) are pre- sented § SEM (n = 3). One-way ANOVA followed by Bonferroni’s post hoc test were used to compare the different treatments. *p < 0.05, **p < 0.01.

Article Snippet: Exposure to 1 and 10mM doxorubicin (DOX) (Selleckchem) for 18 hours was used as positive control.

Techniques: Isolation, Staining, Control, Positive Control, Cytometry